Ketone monitoring to prevent DKA with SGLT2 inhibitors in type 1 diabetes
Treatments studied
Part of Hormones & metabolism, Immune system & allergy clinical trials.
This study tests a device that monitors ketone levels to help reduce the risk of diabetic ketoacidosis (DKA) for people with type 1 diabetes who are taking a class of medications called SGLT-2 inhibitors. The goal is to see if regular ketone tracking can make these medications safer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older and not pregnant
- You have type 1 diabetes
- Your average blood sugar (HbA1c) is below 9%
- You use daily insulin injections, an insulin pump, or a smart insulin system
- You are willing to wear a study device and follow the study schedule
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study is testing a sensor to help prevent diabetic ketoacidosis (DKA), a serious complication of type 1 diabetes. If you join, you'll wear a sensor that checks your glucose and ketones.
This study looks at how stopping a common diabetes drug (SGLT2 inhibitor) affects the body's risk of a serious condition called ketoacidosis. It may help understand who is most at risk and how to prevent it.
This trial tests how combining a ketone supplement with certain diabetes medicines affects blood sugar and ketone levels. It may help adults with type 2 diabetes who are not on insulin or certain other drugs.
This trial tests how stopping a type 2 diabetes medication called an SGLT2 inhibitor affects the liver's production of sugar and ketones. It may help understand better ways to manage diabetes.
This study tests how a drug called canagliflozin (an SGLT2 inhibitor) affects kidney function in people with type 2 diabetes. It involves two kidney biopsies to see how the drug works inside your kidneys, aiming to better protect kidney health.
This study tests a dual continuous ketone and glucose monitor to help prevent diabetic ketoacidosis (DKA) in people with type 1 diabetes who are starting SGLT2 inhibitor treatment. SGLT2 inhibitors are a newer type of diabetes medicine, but they can increase the risk of DKA. The device may make using these medicines safer.
Hear when a new Type 1 diabetes trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.